Drugmaker Eli Lilly & Co. (NYSE: LLY) announced this morning that the company’s solanezumab treatment for Alzheimer’s disease failed to meet both the cognitive and functional endpoints in recently completed phase 3…
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall St. research calls this Monday morning. Annaly Capital Management Inc. (NYSE: NLY) cut to Underperform at Wells Fargo.…
The three major US stock indexes opened mixed this morning with the Nasdaq Composite slightly negative on an unexpectedly weak earnings report from Apple Inc. (NASDAQ: AAPL) (more coverage here). A weak…
Surging growth of its Cymbalta depression treatment helped Eli Lilly & Co. (NYSE: LLY) beat Wall St.’s earnings expectations. But generic rivals to Plavix, other drugs hurt Bristol-Myers Squibb Co. (NYSE: BMY)…
The three major US stock indexes opened roughly flat this morning as Spanish 10-year bond yields rose to 7.5% and Moody’s cut Germany’s outlook to ‘negative’ after the markets closed last night…
A new treatment for Alzheimer’s disease from Pfizer Inc. (NYSE: PFE) and partner Elan Corp. plc (NYSE: ELN) has failed a late-stage trial in patients with mild-to-moderate cases of the disease and…
Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for the first quarter of 2012. The top five sellers include drugs from…
Abbott Laboratories (NYSE: ABT) reported second-quarter results this morning that beat the consensus estimate for earnings per share (EPS), but missed slightly on revenues. The drug maker reported adjusted diluted EPS of…
GlobeImmune, Inc. is the latest biotech to file for an initial public offering. Financial terms were not disclosed but the first filing is for up to $69 million in common stock. This…
Some mergers are very straight-forward, and others are just odd. Now we have an answer over whether or not Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) was going to be acquired or not. Bristol-Myers…
We are now just about two weeks away from the king of biotech and pharma events in cancer treatments. The 2012 annual meeting of the American Society of Clinical Oncology (ASCO) is set…
It is now getting close to the middle of May, and that means one thing for biotech investors. The king of biotech and pharma events is about to take place. The 2012…
Diabetes drug maker Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) has hired bankers and lawyers to help the company find a buyer. In February Amylin turned down a $3.5 billion ($22/share) offer from Bristol-Meyers…
If there was a merger candidate which ever made sense in biotech and pharma it is Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN). News from Bloomberg is out that the company has rejected an offer to…
Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) and Eli Lilly & Co. (NYSE: LLY) are in the news on the diabetes front. The companies have announced that the European Commission has now approved its…
Jon C. Ogg 
